Bagsværd, Denmark, 15 November 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021.
Under the programme initiated 5 November 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 11 November 2021 to 1 February 2022.
Since the announcement of the programme, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| 11 November 2021 | 105,000 | 734.79 | 77,152,736 |
| 12 November 2021 | 105,000 | 735.13 | 77,188,165 |
| Accumulated under the programme | 210,000 | 154,340,901 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com. The appointed lead manager makes its trading decisions concerning the timing of the purchases of the shares independently of Novo Nordisk.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 2,894 B shares in the period from 8 November 2021 to 12 November 2021. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 28,399,732 B shares of DKK 0.20 as treasury shares, corresponding to 1.2% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 3 February 2021. As of 12 November 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 29,646,181 B shares at an average share price of DKK 554.87 per B share equal to a transaction value of DKK 16,449,867,345.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
| Media: | ||
| Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com |
| Michael Bachner (US) | +1 609 664 7308 | mzyb@novonordisk.com |
| Investors: | ||
| Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
| David Heiberg Landsted | +45 3077 6915 | dhel@novonordisk.com |
| Mark Joseph Root (US) | +1 848 213 3219 | mjhr@novonordisk.com |
Company announcement No 74/2021
Attachment
